Piper Jaffray Upgrades Baxter International Inc to Overweight with Price Target $58.00

Brokerage firm Piper Jaffray Upgrades its rating on Baxter International Inc(NYSE:BAX). In a research note issued to the investors, the brokerage major Raises the price-target to $58.00 per share. The shares have been rated Overweight. Previously, the analysts had a Neutral rating on the shares. The rating by Piper Jaffray was issued on Apr 14, 2016.

In a different note, On Feb 3, 2016, BMO Capital said it Maintains its rating on Baxter International Inc. In the research note, the firm Raises the price-target to $33.00 per share. The shares have been rated ‘Market Perform’ by the firm.

Baxter International Inc (BAX) made into the market gainers list on Mondays trading session with the shares advancing 0.96% or 0.41 points. Due to strong positive momentum, the stock ended at $43.1, which is also near the day’s high of $43.245. The stock began the session at $42.53 and the volume stood at 61,44,337 shares. The 52-week high of the shares is $43.44 and the 52 week low is $32.18. The company has a current market capitalization of $23,613 M and it has 54,78,71,850 shares in outstanding.

Baxter International Inc(BAX) last announced its earnings results on Feb 2, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $2.60B. Analysts had an estimated revenue of $2.55B. Earnings per share were $0.43. Analysts had estimated an EPS of $0.32.

Several Insider Transactions has been reported to the SEC. On Apr 6, 2016, John D Forsyth (director) sold 1,887 shares at $41.75 per share price.Also, On Mar 15, 2016, Albert P L Stroucken (director) sold 5,660 shares at $40.33 per share price.On Mar 15, 2016, James R Iii Gavin (director) sold 5,660 shares at $40.34 per share price, according to the Form-4 filing with the securities and exchange commission.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Leave a Reply

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.